Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/12801
Title: Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation
Authors: Arcuri, Leonardo Javier
Schirmer, Marcelo Ribeiro
Nogueira, Marta Colares
Maradei, Simone Cunha
Tavares, Rita de Cássia Barbosa da Silva
Moreira, Maria Cláudia Rodrigues
Araújo, Renato de Castro
Lerner, Decio
Pacheco, Antonio Guilherme Fonseca
Keywords: Citomegalovirus
Citomegalovirus
Transplante de Células-Tronco Hematopoéticas
Hematopoietic Stem Cell Transplantation
Trasplante de Células Madre Hematopoyéticas
Doadores não Relacionados
Unrelated Donors
Donante no Emparentado
Transplante Haploidêntico
Transplantation, Haploidentical
Trasplante Haploidéntico
Issue Date: 2020
Publisher: Biology of Blood and Marrow Transplantation
Citation: ARCURI , Leonardo Javier; SCHIRMER , Marcelo Ribeiro; NOGUEIRA , Marta Colares; MARADEI , Simone Cunha; TAVARES , Rita de Cássia Barbosa da Silva; MOREIRA , Maria Cláudia Rodrigues; ARAÚJO , Renato de Castro; LERNER , Décio; PACHECO , Antônio Guilherme Fonseca. Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation. Biology of Blood and Marrow Transplantation, Chicago, v. 26, n. 11, p. e275-e279, 2020.
Abstract: Cytomegalovirus (CMV) reactivation remains one of the main infectious complications following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role of anti-CMV antibody titers in HSCT from alternative donors and to compare the risk of CMV reactivation between posttransplant cyclophosphamide-based haploidentical HSCT and antithymocyte globulin-based unrelated donor (URD) HSCT. We included 98 CMV-positive patients, 30 undergoing haploidentical HSCT and 68 undergoing URD HSCT. The majority of patients had a malignant disease (84%), received a myeloablative conditioning regimen (78%), and received a bone marrow graft (90%). The median pretransplantation anti-CMV IgG level was 109 U/mL. With median follow-up of 2.2 years, a total of 72 CMV reactivations occurred in 50 patients. There was no difference in CMV reactivation pattern between haploidentical HSCT recipients and URD HSCT recipients. In multivariable analysis until the first event, the incidence of CMV reactivation was higher in patients with anti-CMV IgG levels >100 U/mL (hazard ratio [HR], 2.38; P = .005) and in patients diagnosed with grade II-IV acute graft-versus-host disease (GVHD) (HR, 10.8; P = .003) after day +50 and lower in patients who received higher doses of CD34 cells (HR, .44; P = .006). In multivariable analysis for recurring events, the incidence of CMV reactivation was higher in patients receiving reduced-intensity conditioning (HR, 1.69: P = .04) and in patients with acute GVHD (HR, 1.88; P = .02), and lower in those who received higher doses of CD34 cells (HR, .55; P = .01). In summary, we have shown that pretransplantation anti-CMV IgG titers are correlated with CMV reactivation risk. More studies are needed to assess how this information can be incorporated in HSCT. The use of high-dose cellular grafts, a modifiable risk factor, also protects against CMV reactivation.
Description: p. e275-e279.: tab. p&b.
URI: https://ninho.inca.gov.br/jspui/handle/123456789/12801
ISSN: 2666-6375 (Impresso)
2666-6367 (Online)
Appears in Collections:Artigos de Periódicos da área de Tecido Ósseo e Conectivo



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.